[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-418689-105":59,"doc-detail-418689-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-report-case-report-tislelizumab-induced-panuveitis-a-report-of-two-cases","Case Report - Case Report: Tislelizumab-induced panuveitis - a report of two cases","","Tislelizumab is an increasingly used immunotherapy for malignancies, but it can trigger a rare ocular immune-related adverse event that resembles Vogt-Koyanagi-Harada-like syndrome. Two cancer patients developed severe bilateral vision loss after treatment. Multimodal ocular imaging supported immune checkpoint inhibitor-associated uveitis, specifically VKHLS. Management focused on discontinuing tislelizumab and using local corticosteroids, including transcutaneous periocular triamcinolone acetonide injections and topical steroid eye drops, without systemic corticosteroids. Uveitis resolved rapidly with recovery of visual acuity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-case-report-tislelizumab-induced-panuveitis-a-report-of-two-cases/418689/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-case-report-tislelizumab-induced-panuveitis-a-report-of-two-cases/418689.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition can tislelizumab cause in the eye?","Question",{"text":112,"@type":113},"Tislelizumab can induce a rare ocular immune-related adverse event resembling Vogt-Koyanagi-Harada-like syndrome, presenting as uveitis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the two cases managed?",{"text":117,"@type":113},"Tislelizumab was discontinued and local corticosteroid therapy was used, including transcutaneous periocular triamcinolone acetonide injections and topical steroid eye drops, without systemic corticosteroids.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the outcome after treatment?",{"text":121,"@type":113},"The uveitis resolved rapidly, and visual acuity recovered in both patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},418689,1790718949,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Case Report  \nPUBLISHED 19 December 2025 DOI 10.3389/fphar.2025.1678663  \nOPEN ACCESS  \nEDITED BY  \nMaha Mohamed Saber-Ayad,  \nUniversity of Sharjah, United Arab Emirates  \nREVIEWED BY  \nNianting Tong,  \nQingdao Municipal Hospital, China Hongfei Jiang,  \nQingdao University, China Shuhei Suzuki,  \nYamagata Prefectural Shinjo Hospital, Japan  \n*CORRESPONDENCE  \nKaiyan Zhang,  \n [dinghuan2025@163.com](dinghuan2025@163.com)  \n†These authors share first authorship.  \nRECEIVED 03 August 2025  \nREVISED 26 November 2025  \nACCEPTED 10 December 2025  \nPUBLISHED 19 December 2025  \nCITATION  \nDing H, Zhang S, Lin L and Zhang K (2025) Case Report: Tislelizumab–induced panuveitis: areport of two cases.  \nFront. Pharmacol. 16:1678663 .  \ndoi: 10.3389/fphar.2025.1678663  \nCOPYRIGHT  \n© 2025 Ding, Zhang, Lin and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: Tislelizumab–  \ninduced panuveitis: a report of two cases  \nHuan Ding 1†, Shuyuan Zhang 1†, Lin Lin 2 and Kaiyan Zhang 2*  \n1Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, China, 2Department of Ophthalmology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China  \nBackground: Tislelizumab, an increasingly utilized immunotherapy for a range of malignancies, can induce a rare ocular immune-related adverse event resembling Vogt-Koyanagi-Harada-like syndrome (VKHLS) . Management of complication requires careful balancing with ongoing systemic anti-tumor therapy.  \nCase Presentation: This report describes two cancer patients who developed severe bilateral vision loss following Tislelizumab treatment. Multimodal ocular imaging confirmed the diagnosis of immune checkpoint inhibitors (ICIs) -associated uveitis, specifically a VKHLS. Both patients were managed with discontinuation of Tislelizumab and local corticosteroid therapytranscutaneous periocular injection of triamcinolone acetonide (TA) and topical steroid eye drops, without systemic corticosteroids. Their uveitis resolved rapidly, with recovery of visual acuity.  \nConclusion: Prompt Tislelizumab discontinuation combined with local corticosteroid therapy-transcutaneous periocular TA injections, and topical steroid eye drops may constitute an effective management strategy for ICIsinduced uveitis. This approach is particularly valuable for cancer patients in whom systemic corticosteroids are contraindicated or unsuitable.  \nKEYWORDS  \nimmune checkpoint inhibitors, tislelizumab, triamcinolone acetonide, uveitis, vogtkoyanagi-harada-like syndrome  \n1 Introduction  \nImmune checkpoint inhibitors (ICIs) represent a transformative class of agents in cancer immunotherapy (Leach et al., 1996) . Under physiological conditions, immune checkpoint molecules prevent excessive T-cell activation. Tumor cells, however, can exploit this mechanism by upregulating checkpoint molecules and/or fostering an immunosuppressive microenvironment to evade immune surveillance. ICIs counteract this evasion by blocking checkpoint molecules such as PD-1, PD-L1, and CTLA-4, thereby releasing inhibitory signals on T cells and reactivating intrinsic antitumor immunity paradigm shift in oncology (Dine et al., 2017) .  \nDespite their efficacy, the potentiation of antitumor immunity by ICIs can trigger offtarget autoimmune reactions against healthy tissues, termed immune-related adverse events (irAEs) (Baxi et al., 2018) . Among these, ocular irAEs (OirAEs) remain under-recognized, affecting approximately 2.8%–4.3% of ICIs recipients (Wu et al., 2024) . Clinical manifestations ","cbCaiseqWcDLfzSR","https://ap.wps.com/l/cbCaiseqWcDLfzSR","pdf",1744437,"English","# Introduction\n## Immune checkpoint inhibitors and immune-related adverse events\n## Ocular immune-related adverse events and uveitis\n# Case description\n## Case 1 eye signs and grading\n# Conclusion","[{\"question\":\"What condition can tislelizumab cause in the eye?\",\"answer\":\"Tislelizumab can induce a rare ocular immune-related adverse event resembling Vogt-Koyanagi-Harada-like syndrome, presenting as uveitis.\"},{\"question\":\"How were the two cases managed?\",\"answer\":\"Tislelizumab was discontinued and local corticosteroid therapy was used, including transcutaneous periocular triamcinolone acetonide injections and topical steroid eye drops, without systemic corticosteroids.\"},{\"question\":\"What was the outcome after treatment?\",\"answer\":\"The uveitis resolved rapidly, and visual acuity recovered in both patients.\"}]","Case Report - Case Report: Tislelizumab-induced panuveitis - a report of two cases | PDF",1790613957,18]